Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03665441
Title Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)
Acronym Trybeca-1
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors ERYtech Pharma
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FRA


No variant requirements are available.